Literature DB >> 28498287

Molecular Profiling Reveals a Clonal Relationship Between Ovarian Mucinous Tumors and Corresponding Mural Carcinomatous Nodules.

Nima Mesbah Ardakani1, Tindaro Giardina, Benhur Amanuel, Colin J Stewart.   

Abstract

Benign or malignant mural nodules rarely occur in mucinous tumors (MTs) of the ovary and malignant nodules can show mesenchymal or epithelial differentiation. The histogenesis of mural nodules is unclear and it has been suggested that these may evolve through divergent differentiation of the mucinous neoplasm or alternatively represent a collision phenomenon. To test these possibilities we compared the molecular profile of 7 ovarian MTs with their matched mural carcinomatous nodules (MCNs) by next-generation sequencing. We found identical KRAS mutations in paired MTs and MCNs in 6 cases, one of which also showed identical CDH1 mutations in both components. In 1 tumor a KRAS mutation was detected in the mucinous neoplasm but not in the MCN; however, identical p53 mutations were present in both tumor elements. Unpaired p53 and PTEN mutations were detected only in the MCN in 2 cases, while mutations in p53 and PIK3CA genes were observed only in the MT in 2 cases. The overall comparative genomic profile was consistent with the neoplastic nature of the MCNs and strongly supported their clonal relationship with the more differentiated mucinous neoplasms. MCNs possibly develop through the acquisition of additional genomic alterations, such as p53 and PTEN mutations, resulting in an anaplastic morphologic phenotype. Our findings also suggest that ovarian MTs with MCNs often arise in KRAS mutant neoplasms. However, mutations in other genes such as PIK3CA and CDH1 may play a role in the neoplastic evolution of a subset of these tumors.

Entities:  

Mesh:

Year:  2017        PMID: 28498287     DOI: 10.1097/PAS.0000000000000875

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.

Authors:  Emiko Niiro; Sachiko Morioka; Kana Iwai; Yuki Yamada; Kenji Ogawa; Naoki Kawahara; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2018-01-17

2.  Ovarian mucinous borderline tumor with anaplastic carcinomatous nodules in adolescents.

Authors:  Mengqi Huang; Qian Lv; Jingyan Xie
Journal:  J Ovarian Res       Date:  2022-07-14       Impact factor: 5.506

Review 3.  Anaplastic carcinoma showing rhabdoid features combined with ovarian mucinous borderline cystadenoma: a case report and literature review.

Authors:  Tingting Sun; Liming Tian; Yunyun Guo; Yu Zheng; Linglong Ouyang; Xianbin Zhang; Yingrong Lai; Guofen Yang
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

Review 4.  Recent Insights into Mucinous Ovarian Carcinoma.

Authors:  Francesca Ricci; Roberta Affatato; Laura Carrassa; Giovanna Damia
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

5.  Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.

Authors:  Toshiyuki Okumura; Etuo Muronosono; Masahiko Tsubuku; Yasuhisa Terao; Satoru Takeda; Masanori Maruyama
Journal:  J Ovarian Res       Date:  2018-09-03       Impact factor: 4.234

6.  Mucinous Ovarian Tumors With Anaplastic Mural Nodules: Case Report.

Authors:  Xinxin Zou; Hao Huang; Qingyu Zhang; Zhen Ma; Yumei Chen; Weifeng Wu; Aizhen Fu
Journal:  Front Med (Lausanne)       Date:  2021-12-14

7.  Ovarian mucinous tumor with mural nodules of anaplastic carcinoma: Three case reports.

Authors:  Xiao-Juan Wang; Chun-Yan Wang; Yan-Feng Xi; Peng Bu; Pei Wang
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

8.  Ovarian mucinous tumors with mural nodules: immunohistochemical and molecular analysis of 3 cases.

Authors:  Ying Shao; Qin Liu; Haiyan Shi; Bingjian Lu
Journal:  Diagn Pathol       Date:  2020-04-14       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.